Intec Pharma - Continued confidence in AP-CDLD
Intec Pharma has developed a unique drug delivery platform, the accordion pill (AP) and is enrolling a 420-patient trial of AP-CDLD for Parkinson’s disease (PD), with full enrolment expected in Q318. Many of the adverse effects associated with the treatment of PD with levodopa (the standard of care), such as off-time and troublesome dyskinesia, are directly associated with its pharmacokinetic (PK) profile. Recently released data from two PK studies of AP-CDLD showed their formulation had lower peak serum concentrations and a longer half-life, which should lower these side effects.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.